RAPT - rapt.com Total Debt to Capital
The daily price chart for RAPT Therapeutics, Inc. (RAPT) reflects the 0.02 metric, driven by expectations surrounding dermatitis therapy and the potential for acquisition by industry behemoths. Meanwhile, market caution stems from a strategic development pivot following research pauses. The business relies on AI platforms that automate the creation of anti-tumor compounds, eliminating routine tasks for researchers.
%20-%20All%20Debt%20to%20Shareholders'%20Equity%20Ratio&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261030&filename=GURU_Markets_-_RAPT_-_RAPT-Therapeutics-Inc._-_All-Debt-to-Shareholders-Equity-Ratio "RAPT (RAPT Therapeutics, Inc.) Total Debt to Capital history from 07/04/2022 to 03/14/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for RAPT Therapeutics, Inc.
- price and consensus price forecast:
- market capitalization statistics:
- book capitalization indicators:
- company total debt and liquidity indicators:
Debt to Equity RAPT Therapeutics, Inc.|RAPT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital RAPT Therapeutics|RAPT - Company Aggregate Debts|Debt to Book Value RAPT Therapeutics|RAPT - Company Long-Term Loans and Borrowings|Company Short-Term Debts RAPT Therapeutics|Quick Liquidity rapt.com
- earnings and valuation multiples information:
Basic company analysis:RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. (RAPT) automates immuno-oncology design through robotic bio-screening and AI. The current leverage ratio (total debt to equity) reflects the proportion of borrowed funds relative to the company's own assets. This metric measures financial stability and the extent of the business's dependence on creditors. Analysis of this chart allows for an assessment of the balance between aggressive technological development and debt load. A low ratio confirms the funding autonomy of capital-intensive digital developments.
Competitor analysis for RAPT Therapeutics, Inc.
Debt to Equity argenx|BioNTech Inc. - Aggregate Debt to Equity|Total Debt to Capital ABVX|ADMA (ADMA Corp) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital PTGX (Protagonist Therapeutics)|Total Debt to Capital immunovant.com IMVT|KNSA - Debt to Equity|All Debt to Shareholders' Equity Ratio GRFS (Grifols SA)|Adaptive Biotechnologies Corp (ADPT) - Debt to Equity|Total Debt to Equity Ratio Celldex Corp|AUPH (Aurinia Pharmaceuticals) - Total Debt to Capital|Total Debt to Capital biocryst.com|Total Debt to Equity Ratio VERA (Vera Therapeutics)|DNTH (Dianthus Therapeutics Inc) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital PHVS (Pharvaris Corp)|Total Debt to Capital Coefficient AbCellera (ABCL)|TRML - Debt to Equity|precigen.com (PGEN) - Total Debt to Equity Ratio|Pharming Group (PHAR) - Debt to Equity|Total Debt to Equity Ratio Nektar Therapeutics Inc|Total Debt to Equity Ratio UPB|Total Debt to Capital Zenas Corp|Debt to Equity Immunome, Inc. (IMNM)|gossamerbio.com - Debt to Equity Ratio|Total Debt to Capital KALV (KalVista Pharmaceuticals, Inc.)|Septerna, Inc. (SEPN) - Debt to Capital|PVLA - Debt to Equity|All Debt to Shareholders' Equity Ratio SVRA (Savara Pharma)|RIGL: Total Debt to Capital|anaptysbio.com (ANAB) - Total Debt to Capital|Debt to Equity Astria Therapeutics, Inc.|enGene Holdings Inc - Aggregate Debt to Equity|Total Debt to Equity Ratio JBIO (Aerovate Therapeutics Inc)|Aggregate Debt to Capital ACRS|Kyverna Therapeutics - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio TLSA|CABA: Total Debt to Equity Ratio|Ventyx Biosciences Inc. - Aggregate Debt to Capital|THTX: Total Debt to Capital|Avalo Therapeutics Inc - All Debt to Shareholders' Equity Ratio|ELDN (Eledon Pharmaceuticals) - Total Debt to Capital|Debt to Capital agenusbio.com AGEN|Debt to Equity Climb Bio (CLYM)|ZURA (Zura Bio Ltd) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital ATYR (aTyr)|Total Debt to Capital Adagene Inc ADAG|IMA - Debt to Equity|Aggregate Debt to Equity STTK|EQ: Total Debt to Capital|Debt to Capital Connect Biopharma Holdings Limited (CNTB)|Total Debt to Equity Ratio IMUX|Total Debt to Capital Atara Biotherapeutics Inc|Total Debt to Equity Ratio IFRX (InflaRx N.V.)|Aggregate Debt to Capital XFOR|Total Debt to Capital ACET (Adicet Bio, Inc.)|Total Debt to Capital Coefficient Celularity Inc (CELU)|INmune Bio Corp - Total Debt to Capital|Barinthus Biotherapeutics Corp (BRNS) - Total Debt to Equity Ratio|Kezar Life Sciences (KZR) - Debt to Equity|SABS - Total Debt to Capital Coefficient|Total Debt to Equity Ratio AKTX|ENLV: All Debt to Shareholders' Equity Ratio|Total Debt to Capital QTTB|Total Debt to Capital Coefficient GeoVax Corp|Debt to Equity Edesa Biotech, Inc. EDSA|IBIO: Debt to Equity Ratio|Carisma Tx - Total Debt to Capital|XTL Biopharmaceuticals Ltd (XTLB) - Total Debt to Equity Ratio|BOLT (boltbio.com) - Total Debt to Equity Ratio|HCWB - Total Debt to Capital Coefficient|Debt to Equity Aptevo Therapeutics, Inc.|AIM: All Debt to Shareholders' Equity Ratio|Total Debt to Capital ADTX|Total Debt to Capital GRI Bio Inc (GRI)|Debt to Equity XORTX XRTX|HIND (Vyome Therapeutics) - Aggregate Debt to Equity|REVB: Total Debt to Equity Ratio|indaptusrx.com - Aggregate Debt to Capital|Scinai Immunotherapeutics Ltd. (SCNI) - Debt to Equity|Aggregate Debt to Equity CALI (CalciMedica)|AFMD (Affimed NV) - Total Debt to Capital|ALLK: All Debt to Shareholders' Equity Ratio|Total Debt to Capital HOOK|Total Debt to Capital igmbio.com (IGMS)|Debt to Equity iTeos Therapeutics, Inc. ITOS|All Debt to Shareholders' Equity Ratio OCEA|TCBP - Debt to Equity|Third Harmonic Bio Inc (THRD) - Total Debt to Equity Ratio